Targeted therapy tested for Hard-to-Treat skin cancers
NCT ID NCT01352520
Summary
This study tested whether the drug brentuximab vedotin could help control three types of CD30-positive skin lymphomas in patients whose disease had come back or did not respond to prior treatments. The drug is designed to find and enter cancer cells with a specific marker (CD30) and release a cell-killing agent. Researchers enrolled 79 adults to receive the drug by IV every three weeks and monitored their skin lesions, quality of life, and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.